JW (Cayman) Therapeutics Co (2126) Fair Value & Analysis
Healthcare · HK · Market cap HK$750M
Fair value as of: Aug 5, 2026
From 1 valuation models · updated today
Fair value updated Aug 5, 2026, revised from HK$0.1800 to HK$0.1700 (−5.6%) since Jul 2, 2026. Share price −13.8% over the past month.
Below-average quality, and screening another 90% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (HK$0.2100). The favourable scenario is already priced in.
- Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (HK$0.1100 to HK$0.2100) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 5, 2026.
How to read this chart
60‑month range HK$1.19 – HK$37.05 · fair‑value band HK$0.1100 – HK$0.2100 · the HK$1.62 price screens above the HK$0.1700 fair value. Dashed = 300-day average. As of Aug 5, 2026.
Analysis
JW (Cayman) Therapeutics Co (2126) currently trades at HK$1.62, while our model-based Fair Value estimate is HK$0.1700, implying the stock looks roughly 89.5% overvalued today. We read business quality at 29/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at HK$284M. Revenue grew 148.3% year over year. It earns a return on equity of -64.4%. The balance sheet holds a net cash position of HK$241M. Fundamentals as of Aug 5, 2026
Our scenario range runs from HK$0.1100 (bear case) to HK$0.2100 (bull case); at HK$1.62, the current price sits above that range. The share trades about 75% below its 52-week high and 16% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -90%, 2126 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 5, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 45 · Market factors (momentum, volatility) 2
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People's Republic of China. The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer.
Full company description
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People's Republic of China. The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer. It offers Carteyva, JWCAR201, and JWCAR239 for the treatment of hematological malignancies, advanced relmacabtagene autoleucel injection ("relma-cel") as a potential treatment for systemic lupus erythematosus ("SLE"), and progressed development of products for the treatment of solid tumors, as well as systemic lupus erythematosus (SLE), a chronic autoimmune disease. The company's products pipeline includes JWCAR129, a chimeric antigen receptor (CAR) construct therapy for use in the treatment of multiple myeloma; and JWCAR201, a dual targeting autologous CAR T-cell therapy for use in the treatment of B-cell malignancies and autoimmune diseases. It is also developing JWATM204 and JWATM214 for treating hepatocellular carcinoma (HCC); JWATM203 for the treatment of hepatoblastoma (HB) and hepatocellular carcinoma (HCC) in pediatric patients; JWATM213 for treating HCC; JWTCR001 for the treatment of various solid tumors; and JWCAR031 for the treatment of small cell lung cancer. In addition, the company engages in drug research and development; medical research and experimental development; import and export handling; and clinical trial and CRO, as well as investment holding activities. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
JW (Cayman) Therapeutics Co reported revenue of HK$276M in FY2025 versus HK$30.8M in FY2021, a compound +73.1%/yr. Reported net income was −HK$541M in FY2025.
2126 screens 90% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 848 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Genmab A/S GMAB | kr 1,891 | kr 276.68 | -85% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
Compare JW (Cayman) Therapeutics Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is JW (Cayman) Therapeutics Co (2126) overvalued or undervalued?
What is the fair value of 2126?
What is the quality score of 2126?
What is the revenue of JW (Cayman) Therapeutics Co (2126)?
What is the net profit margin of 2126?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track JW (Cayman) Therapeutics Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.